BIV 201

Drug Profile

BIV 201

Alternative Names: BIV201; Terlipressin acetate continuous infusion

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioVie
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ascites; Liver cirrhosis

Most Recent Events

  • 27 Jul 2017 BioVie files for patent protection for BIV 201 in the treatment of ascites in Japan
  • 15 Jul 2017 Phase-II clinical trials in Ascites and Cirrhosis (Treatment-experienced) in USA (IV) (NCT03107091)
  • 24 May 2017 BioVie receives patent allowance for BIV201 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top